Literature DB >> 32476241

Acquired bleeding disorders.

Andreas Tiede1, Barbara Zieger2, Ton Lisman3.   

Abstract

Acquired bleeding disorders can accompany hematological, neoplastic, autoimmune, cardiovascular or liver diseases, but can sometimes also arise spontaneously. They can manifest as single factor deficiencies or as complex hemostatic abnormalities. This review addresses (a) acquired hemophilia A, an autoimmune disorder characterized by inhibitory autoantibodies against coagulation factor VIII; (b) acquired von Willebrand syndrome in patients with cardiovascular disorders, where shear stress abnormalities result in destruction of von Willebrand factor; and (c) liver function disorders that comprise complex changes in pro- and anti-hemostatic factors, whose clinical implications are often difficult to predict. The article provides an overview on the pathophysiology, diagnostic tests and state-of-the-art treatment strategies.
© 2020 The Authors. Haemophilia published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Coagulation Protein Disorders; Hemophilia A; Liver disease; Von Willebrand Disease

Mesh:

Substances:

Year:  2020        PMID: 32476241     DOI: 10.1111/hae.14033

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1. 

Authors:  Roy Khalife; Lisa Duffett; Tzu-Fei Wang; Alan Tinmouth
Journal:  CMAJ       Date:  2021-10-25       Impact factor: 8.262

2.  Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines.

Authors:  Julia R Hirsiger; Maria Martinez; Dimitrios A Tsakiris; Micol G Cittone; Lukas Graf; Johannes Oldenburg; Behnaz Pezeshkpoor; Mike Recher; Jens Mueller; Bernhard Gerber; Christoph T Berger
Journal:  J Thromb Haemost       Date:  2022-02-13       Impact factor: 16.036

3.  New onset of acute heavy menstrual bleeding in a 34-year-old woman.

Authors:  Roy Khalife; Lisa Duffett; Tzu-Fei Wang; Alan Tinmouth
Journal:  CMAJ       Date:  2021-08-03       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.